[ET Net News Agency, 22 February 2021] UOB Kay Hian lifted its target price for Alibaba
Health Information Technology (00241) to HK$31 but downgraded its rating to "hold" from
"buy" after the recent rally.
The research house expects Ali Health to report strong revenue and adjusted earnings
growth of 75.4% and 272% respectively in FY2021. The company has achieved a turnaround
from loss to profit in 1H FY2021 and continues to experience substantial expansion with
improving profitability.
UOBKH said Ali Health's prescription drug sales business has achieved rapid growth and
has become a new driver of long-term sustainable growth. Meanwhile, the company has
launched the "Dr. Deer" app and aims to provide professional and reliable healthcare
services with extensive online and offline networks.
UOBKH estimated Ali Health will continue to deliver robust revenue growth of 56.9% CAGR
in FY2021-23. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00241 ALI HEALTH
Nominal 
2.610 -0.040 (-1.509%) Research Report
22/02/2021 13:54
{I-bank focus}UOBKH lifts Ali Health (00241) to HK$31
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |